CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies
Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced its participation in CANCERPREV, a research and training program composed of top-tier research and teaching institutions and life science/pharma companies. CANCERPREV is principally focused on advancing the understanding of how breast and skin cancer can be prevented.
Life science researchers participating in CANCERPREV programs receive cross-disciplinary training from cancer biologists, epidemiologists, mathematicians and geneticists to better understand the key factors in cancer development, including hormonal stimulation, chronic inflammation and lifestyle risks. A central focus of the consortium’s research is on examining sex hormone signaling and chronic inflammation in breast tissue and skin as benchmarks of early cancer development in organs with reproductive and non-reproductive functions, respectively.
The European Commission recently granted CANCERPREV funding under its Horizon 2020 research and innovation program.
As a member of the consortium, Fluidigm is providing researchers with training and support to maximize the knowledge-generating power of the company’s cutting-edge mass cytometry and microfluidics technologies. These technologies include the Helios™ system and Hyperion™ Imaging System, which employ mass cytometry, and the Juno™ and Biomark™ microfluidics systems, all of which are used throughout the academic and private sector research and drug development communities to advance the discovery and deployment of cancer biomarkers.
“Fluidigm is pleased for the opportunity to participate in CANCERPREV, and we are excited to support the consortium’s efforts to communicate meaningful oncology and immuno-oncology insights more broadly throughout the life science research community,” said Roberto Spada, PhD, who leads business development for Fluidigm in Europe and the Middle East. “Ultimately, our goal is to contribute to the acceleration of timelines for drug development and implementation of new therapies for cancer prevention.”
“Cancer knows no boundaries, and with rates continuing to increase globally, now more than ever we need to better understand the key factors in cancer development in order to properly prevent this disease,” said Gian Paolo Dotto, MD, PhD, University of Lausanne, one of the principal investigators of the consortium. “We’re grateful for the training, support and technology Fluidigm is providing across a wide range of instruments and systems, and look forward to continuing to work together towards our mission of building a global foundation of cancer knowledge.”
In addition to Fluidigm, partners in the CANCERPREV consortium include the International Cancer Prevention Institute, Helsana Insurance Group, The Middle East Children’s Institute International, Haute Ecole Spécialisée de Suisse Occidentale (HES-SO) – La Source, University of Southern Denmark, AstraZeneca UK Limited and Swiss Vitamin Institute.
“Fluidigm’s industry-leading mass cytometry and microfluidics technologies are helping to advance research for diagnosis and treatment of patients with cancer, but we recognize that prevention is the most powerful tool we have against a disease that is the second leading cause of death on a global basis,” said Chris Linthwaite, President and CEO of Fluidigm. “We are proud to partner with CANCERPREV to support the next generation of researchers, and our team is eager to support discovery of prevention insights that may inform new therapies and save lives.”
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Biomark, CyTOF, Helios, Hyperion, and Juno are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding potential advancements in research through Fluidigm’s mass cytometry and microfluidics technologies and expectations for participation in a research consortium. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.